COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
CPTx appoints Matt Kane as Chief Financial Officer
08/09/2026
Experienced gene editing and cell therapy pioneer to head financing and strengthen strategic leadership for CPTx non-viral DNA-based in vivo CAR T platform Munich, Germany & San Francisco, California – September 8, [...]
Renexxion to Present at H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
LOS ALTOS, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Renexxion, Inc. (“Renexxion”), a late-stage clinical biopharmaceutical company building leadership in the development of treatments for GI motility disorders, [...]
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
08/09/2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics , a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board [...]
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
08/09/2026
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive [...]
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
08/09/2026
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a [...]
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
08/09/2026
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
08/09/2026
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global [...]
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
08/09/2026
Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology [...]
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for [...]
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
08/09/2026
AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients [...]
Merakris Therapeutics Launches Patent-Pending AmnioSurge™ With 360 Medical, Opening New Surgical Revenue Channel
08/09/2026
Procedure-specific biologic technology combines surgeon training, scalable tissue processing and a capital-efficient commercialization model RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Merakris [...]
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
08/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to [...]
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
08/09/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized [...]
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
08/09/2026
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin [...]
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“ Optimi ” or the “ Company ”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic [...]
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
08/09/2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present [...]
Sparrow Pharmaceuticals Appoints George Eldridge as Chief Financial Officer
08/09/2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the appointment of George Eldridge as Chief Financial Officer. Mr. Eldridge brings [...]
Bone Biologics Expands Trial Sites
08/09/2026
Addition of three sites strengthens expectation to complete enrollment by year-end 2026 BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “ [...]

Pages